Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
1. Sionna initiates Phase 1 trial for SION-451 with dual combinations. 2. Topline data expected by mid-2026 will guide Phase 2b trials. 3. SION-451 aims to stabilize CFTR through novel NBD1 combinations. 4. Advancements may significantly improve treatment for cystic fibrosis patients. 5. Current therapies do not sufficiently stabilize the NBD1 domain.